Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary progressive multiple sclerosis : current and future treatment options.

Siobhan M Leary1, Alan J Thompson

  • 1Institute of Neurology, University College London, Queen Sqaure, London, UK.

CNS Drugs
|May 24, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial.

Health technology assessment (Winchester, England)·2026
Same author

Concerns regarding the 2024 revisions of the McDonald criteria for diagnosis of multiple sclerosis - Authors' reply.

The Lancet. Neurology·2026
Same author

Anti-Nogo-A NG101 treatment induces changes in spinal cord micro- and macrostructure following spinal cord injury.

Nature communications·2026
Same author

Performance of the 2024 McDonald Criteria in Patients Under Evaluation for Suspected Multiple Sclerosis.

Neurology·2026
Same author

Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial.

Lancet (London, England)·2025
Same author

Single-centre, prospective cohort to predict optimal individualised treatment response in multiple sclerosis (POINT-MS): a cohort profile.

BMJ open·2025
Same journal

Impact of Omaveloxolone on Serum Lipids in Patients with Friedreich Ataxia: A 1-Year Real-World Analysis.

CNS drugs·2026
Same journal

Emerging Pharmacological Strategies for Trigeminal Neuralgia.

CNS drugs·2026
Same journal

Psychiatric Symptoms Associated with Corticosteroid Use: A Systematic Review and Meta-analysis.

CNS drugs·2026
Same journal

Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD.

CNS drugs·2026
Same journal

Isoform-Specific NaV Modulation in Painful Chemotherapy-Induced Neuropathy: Promise, Limitations, and a Clinical Agenda.

CNS drugs·2026
Same journal

Correction: Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy.

CNS drugs·2026
See all related articles

Designing treatments for primary progressive multiple sclerosis (PPMS) is challenging due to rarity and lack of effective therapies. Future treatments for PPMS should focus on neuroprotection rather than inflammation.

Area of Science:

  • Neuroscience
  • Clinical Neurology
  • Immunology

Background:

  • Primary progressive multiple sclerosis (PPMS) affects approximately 10% of MS patients, characterized by continuous neurological decline.
  • Therapeutic trial design for PPMS faces challenges including patient recruitment difficulties and a lack of specific diagnostic criteria.
  • Validated outcome measures, such as the MS functional composite and MRI-based assessments, are increasingly utilized.

Purpose of the Study:

  • To review the challenges and progress in designing therapeutic trials for primary progressive multiple sclerosis.
  • To evaluate past and ongoing treatment strategies for PPMS.
  • To propose future directions for drug development targeting PPMS pathogenesis.

Main Methods:

  • Review of existing literature on clinical trials and therapeutic agents for PPMS.

Related Experiment Videos

  • Analysis of challenges in patient recruitment and outcome measure selection for PPMS studies.
  • Discussion of potential pathogenic mechanisms and targeted therapeutic approaches for PPMS.

    • Main Results:

    • Several clinical trials have been conducted for PPMS using agents like interferon-beta, mitoxantrone, glatiramer acetate, and riluzole.
    • Patients with PPMS have also been included in trials for other progressive MS therapies, but no treatment has definitively altered the disease course.
    • Current therapeutic strategies have not yet proven effective in modifying the progression of PPMS.

    Conclusions:

    • No definitive treatment has been established to modify the course of primary progressive multiple sclerosis.
    • Future therapeutic agents for PPMS should aim to target the underlying pathogenic mechanisms, potentially focusing on neuroprotection due to reduced inflammation.
    • Further research into PPMS pathogenesis is crucial for guiding the development of effective future treatments.